Trial Profile
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Heartburn
- Focus Therapeutic Use
- Sponsors Takeda
- 27 Mar 2018 Status changed from recruiting to completed.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.
- 23 Aug 2016 New trial record